Safety Profile of Stromal Hydration of Clear Corneal Incisions with Cefuroxime in the Mouse Model.
The use of sutureless clear corneal incisions (CCIs) for phacoemulsification is an established surgical technique, but the dynamic morphology of the wound and poor construction can lead to an increased risk of postoperative endophthalmitis. Stromal hydration with balanced salt solution (BSS) can improve the self-sealing status. Intracameral cefuroxime has reduced endophthalmitis rates. This study investigates the safety profile of stromal hydration with cefuroxime, as sequestering antibiotic at the wound may potentially provide added protection against infection.



MF-1 mice underwent bilateral CCI, followed by stromal hydration with 5 μL of 10 mg/mL cefuroxime, cefuroxime-texas red conjugate (for detection using confocal microscopy), or BSS. Corneas were harvested from 1 h to 12 weeks postoperatively; gross morphology, histology, and apoptotic cell death levels were investigated to determine the safety profile. Bactericidal activity of cefuroxime was assayed using homogenized whole cornea following stromal hydration at 1 h, 24 h, and day 7 against gram-negative Escherichia coli.



Cefuroxime stromal hydration did not alter corneal morphology, with no evidence of corneal scarring or vascularization. Corneal histology and levels of apoptosis were minimal and comparable to the BSS groups up to 12 weeks. Confocal microscopy detected cefuroxime-texas red up to 1 week surrounding the corneal wound. Whole corneal tissue homogenates displayed bactericidal activity up to 24 h postoperatively.



Stromal hydration of CCI with cefuroxime is safe in mouse corneas. A reservoir of antibiotic at the wound can potentially act as a barrier of defense against infection following cataract and associated ocular surgery.
1 Department of Ocular Biology and Therapeutics, UCL Institute of Ophthalmology , London, United Kingdom .|2 Moorfields Eye Hospital NHS Foundation Trust , London, United Kingdom .
Mariya
M
Moosajee
1 Department of Ocular Biology and Therapeutics, UCL Institute of Ophthalmology , London, United Kingdom .
Dhani
D
Tracey-White
3 German Cancer Research Center (DKFZ) , Heidelberg, Germany .
Richard P
RP
Harbottle
4 Imperial College Healthcare NHS Trust , London, United Kingdom .
Veronica
V
Ferguson
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D002444:Cefuroxime / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D003319:Corneal Stroma / Q000601:surgery*; D004926:Escherichia coli / Q000187:drug effects; D056965:Injections, Intraocular; D019654:Lens Implantation, Intraocular; D051379:Mice; D008817:Mice, Mutant Strains; D008826:Microbial Sensitivity Tests; D023421:Models, Animal; D012449:Safety
D000900:Anti-Bacterial Agents; D002444:Cefuroxime